Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMGN |
---|---|---|
09:32 ET | 67097 | 250.57 |
09:34 ET | 15760 | 250.03 |
09:36 ET | 11007 | 250 |
09:38 ET | 3669 | 249.05 |
09:39 ET | 9593 | 249.14 |
09:41 ET | 6000 | 248.24 |
09:43 ET | 8240 | 248.24 |
09:45 ET | 4272 | 248.34 |
09:48 ET | 9499 | 248.2995 |
09:50 ET | 2730 | 248.69 |
09:52 ET | 8438 | 248.87 |
09:54 ET | 5753 | 249.44 |
09:56 ET | 5897 | 249.77 |
09:57 ET | 3300 | 249.99 |
09:59 ET | 6945 | 250.48 |
10:01 ET | 4846 | 250.14 |
10:03 ET | 5905 | 249.89 |
10:06 ET | 4416 | 249.78 |
10:08 ET | 10062 | 249.91 |
10:10 ET | 5674 | 249.88 |
10:12 ET | 8518 | 250.0522 |
10:14 ET | 5612 | 250.11 |
10:15 ET | 4822 | 250.45 |
10:17 ET | 3901 | 250.6858 |
10:19 ET | 3455 | 250 |
10:21 ET | 5494 | 250.03 |
10:24 ET | 9241 | 249.78 |
10:26 ET | 4722 | 249.82 |
10:28 ET | 5149 | 249.81 |
10:30 ET | 1477 | 250.16 |
10:32 ET | 7456 | 250.07 |
10:33 ET | 5021 | 249.94 |
10:35 ET | 5682 | 249.9 |
10:37 ET | 11061 | 249.47 |
10:39 ET | 6221 | 249.46 |
10:42 ET | 5925 | 249.37 |
10:44 ET | 10349 | 249.2454 |
10:46 ET | 2400 | 249.17 |
10:48 ET | 6150 | 249.2 |
10:50 ET | 9606 | 248.793 |
10:51 ET | 11558 | 248.59 |
10:53 ET | 22740 | 248.89 |
10:55 ET | 4406 | 249.19 |
10:57 ET | 6565 | 249.315 |
11:00 ET | 6340 | 249.32 |
11:02 ET | 5066 | 249.29 |
11:04 ET | 4868 | 249.22 |
11:06 ET | 4900 | 249.09 |
11:08 ET | 6208 | 249.24 |
11:09 ET | 8215 | 249.54 |
11:11 ET | 3704 | 249.26 |
11:13 ET | 8430 | 249.3562 |
11:15 ET | 6608 | 249.52 |
11:18 ET | 3377 | 249.5487 |
11:20 ET | 6653 | 249.5 |
11:22 ET | 6807 | 249.137 |
11:24 ET | 5048 | 248.97 |
11:26 ET | 5709 | 248.85 |
11:27 ET | 2773 | 248.455 |
11:29 ET | 3843 | 249.05 |
11:31 ET | 5468 | 249.53 |
11:33 ET | 7629 | 249.71 |
11:36 ET | 6714 | 250.005 |
11:38 ET | 5299 | 249.935 |
11:40 ET | 2376 | 249.89 |
11:42 ET | 5403 | 250.18 |
11:44 ET | 3638 | 249.8688 |
11:45 ET | 3385 | 249.99 |
11:47 ET | 5161 | 249.73 |
11:49 ET | 3246 | 249.64 |
11:51 ET | 1956 | 249.53 |
11:54 ET | 4146 | 249.67 |
11:56 ET | 1180 | 249.69 |
11:58 ET | 3107 | 249.63 |
12:00 ET | 2052 | 249.62 |
12:02 ET | 2106 | 249.63 |
12:03 ET | 3301 | 249.61 |
12:05 ET | 3400 | 249.62 |
12:07 ET | 2600 | 249.49 |
12:09 ET | 6154 | 249.45 |
12:12 ET | 5415 | 249.46 |
12:14 ET | 2484 | 249.74 |
12:16 ET | 2003 | 249.87 |
12:18 ET | 1908 | 249.66 |
12:20 ET | 2323 | 249.65 |
12:21 ET | 500 | 249.7 |
12:23 ET | 1300 | 249.66 |
12:25 ET | 2375 | 249.67 |
12:27 ET | 1664 | 249.55 |
12:30 ET | 400 | 249.5 |
12:32 ET | 1300 | 249.27 |
12:34 ET | 2700 | 249.43 |
12:36 ET | 1249 | 249.445 |
12:38 ET | 1860 | 249.47 |
12:39 ET | 1569 | 249.61 |
12:41 ET | 2293 | 249.4 |
12:43 ET | 2000 | 249.34 |
12:45 ET | 1383 | 249.21 |
12:48 ET | 1300 | 248.99 |
12:50 ET | 5362 | 249.07 |
12:52 ET | 1894 | 249.0199 |
12:54 ET | 1796 | 249 |
12:56 ET | 2532 | 249.06 |
12:57 ET | 1751 | 249.21 |
12:59 ET | 1409 | 249.45 |
01:01 ET | 1522 | 249.46 |
01:03 ET | 1700 | 249.55 |
01:06 ET | 3613 | 249.4 |
01:08 ET | 3830 | 249.35 |
01:10 ET | 3990 | 249.51 |
01:12 ET | 1392 | 249.36 |
01:14 ET | 1973 | 249.435 |
01:15 ET | 1047 | 249.37 |
01:17 ET | 3623 | 249.04 |
01:19 ET | 3509 | 248.95 |
01:21 ET | 1798 | 248.97 |
01:24 ET | 2127 | 249.2331 |
01:26 ET | 1700 | 249.21 |
01:28 ET | 2135 | 249.15 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amgen Inc | 132.2B | 24.5x | +0.08% |
Sanofi SA | 137.0B | 19.9x | +7.84% |
Bristol-Myers Squibb Co | 162.2B | 27.3x | +3.27% |
AstraZeneca PLC | 202.6B | -200.8x | -50.95% |
GSK plc | 111.7B | 17.8x | +36.01% |
Viatris Inc | 14.3B | 85.0x | --- |
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine). It focuses on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease and neuroscience. Its product candidates in Phase III include Erenumab for episodic migraine, Aranesp for myelodysplastic syndromes, BLINCYTO for acute lymphoblastic leukemia and IMLYGIC for metastatic melanoma.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $132.2B |
---|---|
Revenue (TTM) | $26.3B |
Shares Outstanding | 534.2M |
Dividend Yield | 3.11% |
Annual Dividend Rate | 7.7600 USD |
Ex-Dividend Date | 05-16-22 |
Pay Date | 06-08-22 |
Beta | 0.54 |
EPS | $10.16 |
Book Value | $12.00 |
P/E Ratio | 24.5x |
Price/Sales (TTM) | 5.0 |
Price/Cash Flow (TTM) | 14.5x |
Operating Margin | 30.44% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.